18.09.2019 |
Martin Dempster, Noleen K McCorry, Michael Donnelly, Keith Barton, Augusto Azuara-Blanco
בשל "הגנת זכויות יוצרים", מובא להלן קישור למאמר בלבד. לקריאתו בטקסט מלא, אנא פנה לספרייה הרפואית הזמינה לך.
Glaucoma is a slow progressive condition that adversely affects quality of life (QoL). According to the European Glaucoma Society, ‘ the goal of glaucoma treatment is to maintain the patient’s visual function and related quality of life, at a sustainable cost’.
Treatment goals are expected to take patients’ QoL into consideration: ‘Target intraocular pressure (IOP) is the upper limit of the IOP estimated to be compatible with a rate of progression sufficiently slow to maintain vision-related quality of life in the expected lifetime of the patient’.